Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHALCON-EE: Vonoprazan vs Lansoprazole in Erosive Esophagitis
NCT04124926Phase 3Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of vonoprazan in erosive esophagitis (EE) (5 arms), sponsored by Phathom Pharmaceuticals. Primary endpoints: Percentage of Participants Who Had Complete Healing of EE by Week 8 and Percentage of Participants Who Maintained Complete Healing of EE at Week 24. Started Oct 2019; status: completed.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on NCT04124926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124926.